The “Black Straight-Line Sign” in the Putamen in Diffusion-Weighted Imaging: A Potential Diagnostic MRI Marker for Multiple System Atrophy

Yiming Zheng\(^1,2,\) Xiwen Wang\(^1,3\), Huajian Zhao\(^1,4\), Yanyan Jiang\(^1,2\), Ying Zhu\(^5\), Jing Chen\(^1,2\), Wei Sun\(^1,2\), Xiaoxia Wang\(^1,2*\) and Yunchuang Sun\(^1,2*\)

\(^1\)Department of Neurology, Peking University First Hospital, Beijing, China, \(^2\)Beijing Key Laboratory of Neurovascular Disease Discovery, Beijing, China, \(^3\)Department of Neurology, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Hebei, China, \(^4\)Department of Neurology, University of Chinese Academy of Sciences Shenzhen Hospital (Guangming), Shenzhen, China, \(^5\)Department of Radiology, Peking University First Hospital, Beijing, China

Background and Purpose: The diagnosis of multiple system atrophy (MSA) remains challenging in clinical practice. This study investigated the value of hypointense signals in the putamen (“black straight-line sign”) in diffusion-weighted imaging (DWI) of brain MRI for distinguishing MSA from Parkinson’s disease (PD).

Methods: We retrospectively enrolled 30 MSA patients, 30 PD patients, and 30 healthy controls who had undergone brain MRI between 2016 and 2020. Two readers independently assessed the signal intensity of the bilateral putamen on DWI. The putaminal hypointensity was scored using 4-point visual scales. Putaminal hypointensity and the presence of a “black straight-line sign” were statistically compared between MSA and PD or healthy controls.

Results: The mean scores of putaminal hypointensity in DWI in the MSA group were significantly higher than in both the PD (\(U = 315.5, P = 0.034\)) and healthy control groups (\(U = 304.0, P = 0.022\)). Uni- or bilateral putaminal hypointensity in DWI with a score \(\geq 2\) was identified in 53.3\% (16/30), 16.7\% (5/30), and 13.3\% (4/30) of MSA, PD, and healthy controls, respectively, with significant differences between MSA and PD (\(X^2 = 8.864, P = 0.003\)) or healthy controls (\(X^2 = 10.800, P = 0.001\)). Notably, the “black straight-line sign” of the putamen was observed in 16/30 (sensitivity 53.3\%) patients with MSA, while it was absent in PD and healthy controls (specificity 100\%). There were no significant differences for the presence of “black straight-line sign” in the MSA-P and MSA-C groups (\(X^2 = 0.433, P = 0.510\)).

Conclusion: The “black straight-line sign” of the putamen in DWI of head MRIs has the potential to serve as a diagnostic marker for distinguishing MSA from PD.

Keywords: multiple system atrophy, diffusion-weighted imaging, MRI, putamen hypointensive signal, Parkinson’s disease
INTRODUCTION

Multiple system atrophy (MSA) is a rare neurodegenerative disease with the pathological hallmark of oligodendrocyte inclusion bodies (GCI) composed of alpha-synuclein aggregation (1). Clinically, the main manifestations of MSA are autonomic dysfunction superimposed with motor disorders of varying extent, specifically either Parkinsonian type (MSA-P) with Parkinson’s syndrome as the main manifestation and cerebellar type (MSA-C) with cerebellar ataxia as the main manifestation (1). The MSA diagnostic criteria were revised in 2008 by Gilman et al. (2); however, its diagnosis remained challenging for clinical neurologists. For example, when autonomic dysfunction is not obvious until the advanced stage or when it only manifests as isolated Parkinsonism or cerebellar ataxia (1, 3, 4). It is therefore difficult to distinguish MSA from other Parkinsonisms, such as idiopathic Parkinson’s disease (PD), progressive supranuclear palsy, and progressive ataxia such as spinocerebellar ataxia (1, 4, 5). Despite being the focus of various studies, the biomarkers used for MSA diagnosis, such as detection of alpha-synuclein in serum or cerebrospinal fluid, still lack generalized application and their accuracy remains unconfirmed (6, 7). Imaging findings play an important role in the diagnosis of MSA. The classic “hot cross bun” sign, “hyperintense putaminal rim” sign, cerebellopontine atrophy, an abnormally high signal in the pontine peduncle, and other abnormalities that reflect neuronal cell death and gliosis on structural magnetic resonance images (MRI) are widely known, but they are not specific to MSA (8, 9). The application of functional MRI has a certain diagnostic value, but it is difficult to perform these complicated examinations and analyses in routine clinic conditions (10, 11). Recent research has revealed that a hypointense putaminal signal on susceptibility-weighted imaging (SWI) of MRI is of great significance in the diagnosis of MSA (12, 13). A signal hypointensity score over 2 [unilateral or bilateral, a score of 2 when the intensity was similar to the Vein of Galen and with a posterolateral gradient; and score of 3 when marked posterolateral to anteromedial hypointensity (13)] in the putaminal margin is specific to MSA. Currently, we also find that there are MSA patients who also have similar hypointense signals in the putamen on the diffusion-weighted imaging (DWI) sequences and the low signals at the edge of the putamen show a straight distribution—which we term the “black straight-line sign”. The characteristics of the “black straight-line sign” and its diagnostic value in MSA remains unknown. The current study explored the characteristics of the putaminal “black straight-line sign” and its differential diagnosis between MSA, PD, and normal controls.

MATERIALS AND METHODS

This study was approved by the ethics committee of Peking University First Hospital in accordance with the Declaration of Helsinki. Each participant or their legal guardians signed a written informed consent before participating in the study.

Subjects and Patient Consents

This was a retrospective study undertaken in the department of neurology at the Peking University First Hospital. Thirty consecutive inpatients with MSA, 30 non-consecutive inpatients with PD, and 30 age-matched, normal, healthy controls were enrolled from 2016 to 2020. The MSA patients were diagnosed as "probable MSA" based on the second consensus clinical criteria (2). The MSA group included 19 MSA-P (predominant Parkinsonian features) and 11 MSA-C (predominant cerebellar features) patients. The PD patients were diagnosed using the Movement Disorder Society Criteria and all PD patients fulfilled with the clinically established PD (14). All MSA and PD patients were clinically assessed at the first visit and confirmed the diagnosis again during this study by an experienced neurologist (JC, YS, and ZW). All the healthy controls reported no major neurological or psychiatric diseases and none of the positive signs were detected during neurological examinations. The following demographic and clinical information of the MSA and PD subjects, including gender, age at evaluation, disease duration, and Hoehn and Yahr (H-Y) stages (15), were abstracted from medical records.

MRI Protocol and Image Evaluation

All participants underwent a 1.5 or 3.0 Tesla MRI scanning (MAGNETOM Aera 1.5T Siemens Healthcare, Erlangen, Germany. Ingienia 3.0T, Philips Medical Systems, Netherlands). The parameters of DWI of the 1.5 T MR were as follows: repetition time (TR) = 7,280 ms; echo time (TE) = 81 ms; slice number = 20; slice thickness = 6 mm slice gap = 0.9 mm; flip angle = 180; field of view (FOV) = 240 × 240 mm2; voxel size = 1.3 × 1.3 × 6 mm. The parameters of DWI of the 3.0 T MR were as follows: repetition time (TR) = 4,000 ms; echo time (TE) = 72 ms; slice number = 20; slice thickness = 6 mm slice gap = 1 mm; flip angle = 90; field of view (FOV) = 230 × 230 mm2; voxel size = 1.44 × 1.44 × 6 mm; NSA = 1.

The signal intensity and the location of each putaminal abnormality on the DW images were evaluated separately by two readers with 14 and 8 years of neuroimaging MRI research experience (YS and MYZ) in a blind manner in which the demographic and disease information were concealed. If the score of the evaluation was inconsistent between the two readers in a given subject, the final grade for analysis was decided by a consensus between them. The evaluation process is detailed as follows:

First, we assessed the margin of the putamen on DW images, the evaluation of which was similar to SWI assessment (Figure 1) (12): Score of 0: the intensity was normal, no hypointense signal was observed; Score of 1: the intensity was similar to cerebrospinal fluid and without a posterolateral gradient; Score of 2: the intensity was similar to cerebrospinal fluid with a posterolateral gradient; Score of 3: the intensity was similar to cerebrospinal fluid with a marked gradient of posterolateral to anteromedial hypointensity. A hypointense signal score over 2 in the putaminal margin was considered a criterion for an MSA diagnosis. If the scores of the two sides (right/left) differed, the higher score of the unilateral side and the mean score of both sides were calculated separately. The scores were graded previously to the imaging analysis. Second, we assessed the shape of the putaminal margin hypointensity in subjects with a score ≥2. If the low signal at the edge of the putamen showed a straight distribution (the “black straight-line sign”), it was considered a
FIGURE 1 | Scores of putaminal hypointensity in DWI and the corresponding SWI sequence. Left, DWI sequence; right, SWI sequence. (A) DWI and SWI score are all 0 as shown by an arrow; (B) DWI and SWI score are all equal to 1; (C) DWI and SWI scores are all 2 points, and in a straight distribution; (D) DWI and SWI scores are all 2, but with an arc shape and an unclear boundary; (E) from a PD patient, with a DWI score of 1 and SWI score of 2. DWI, diffusion-weighted imaging; SWI, susceptibility-weighted imaging. All illustrations are denoted as arrow.

FIGURE 2 | The “black straight-line sign” on DWI for MSA patients. (A–C) show the “black straight-line sign” from mild to obvious, showing a linear, abnormally low signal with a clear border in the putamen (arrow). The most obvious section is at the fornix. The “black straight-line sign” can be asymmetric (B) or symmetric (C). (D) shows the hypointense putamen signal distributed in an arc in a healthy control subject. MSA, multiple system atrophy. All illustrations are denoted as arrow.

criterion for diagnosing MSA. If the low signal at the edge of the putamen was distributed in an arc, it was considered as a non-MSA abnormal signal (Figures 1, 2).

Third, other image parameters including SWI scores of putaminal hypointensity (12), hyperintense putaminal rim, hyperintensity of the pons (“hot cross bun” sign, including only
The black straight-line sign was compared among the three groups, and there were no significant differences in the proportion of cases with the “black straight-line sign” present between the MSA-P and MSA-C groups. No significant differences in age (t = −0.837, P = 0.410), disease duration (U = 84.500, P = 0.257), Hoehn and Yahr stage (U = 70.500, P = 0.085), or 1.5T/3.0T MRI (X^2 = 1.265, P = 0.261) were observed between “black straight-line sign” positive and negative MSA patients. Except for SWI scores of putaminal hypointensity ≥2 (X^2 = 6.000, P = 0.014), none of the other image parameters (i.e., hyperintense putaminal rim, hyperintensity of thepons, and brain stem atrophy) showed a significant difference between “black straight-line sign” positive and negative groups.

DISCUSSION

To our knowledge, this is the first study to assess the diagnostic value of hypointense putaminal signals in DWI between MSA, PD, and normal controls. Our results demonstrate that a score higher than 2, especially in the presence of a “black straight-line sign”, can differentiate MSA from PD and normal people. The “black straight-line sign” was specific to both MSA-P and MSA-C subgroups.

The hypointense signal in the posterior putamen was first noticed in the SWI sequence in MSA patients (12, 13, 18). Previous studies have found that this abnormal signal (unilateral or bilateral) with a score higher than 2 had high specificity in the diagnosis of MSA-P, although the sensitivity was relatively low (12, 13). We observed similar hypointense signal manifestations in DWI sequences among MSA patients in clinical practice, so we used a grading method similar to that used in SWI research in our study. Similar to the SWI studies, the current study found that the proportion of hypointense signals with a score ≥2 (unilateral or bilateral) in the posterior putamen in MSA was significantly higher than that in PD and normal healthy controls. However, we also found a high proportion of hypointense signals with scores over 2 in both PD and normal controls. After further assessment, we found that the morphological characteristics of this putaminal hypointensity in PD and normal controls were rather different from those in MSA. In MSA patients, the morphology of the hypointense signal was thin, straight, and bordered by the surrounding structure (i.e., black straight-line sign). On the contrary, in patients of PD and normal controls, the morphology of the hypointense signal was thick, with an arcuate shape consistent with the anatomical structure, and with a vague boundary with the surrounding normal structure. When the black straight sign was compared among the three groups, it was found that this sign only existed in patients with MSA, but not in PD and normal controls. Our results also show that although the sensitivity of the "black straight-line sign" is limited, its high specificity may be a novel imaging manifestation in the diagnosis of MSA.
TABLE 1 | Demographic characteristics of the subject groups.

|            | MSA (n = 30) | MSA-P (n = 19) | MSA-C (n = 11) | PD (n = 30) | HCs (n = 30) | MSA vs. PD | MSA vs. HCs |
|------------|--------------|---------------|----------------|-------------|-------------|------------|-------------|
| Age (y)    | 62.2 ± 8.6   | 62.4 ± 9.3    | 61.9 ± 7.6     | 65.9 ± 6.9  | 60.0 ± 9.3  | t = −1.854, p = 0.069 | t = 0.965, P = 0.339 |
| Gender (Male) | 12 (40%) | 9 (45%) | 3 (27%) | 14 (46.7%) | 13 (43%) | X² = 0.271, P = 0.602 | X² = 0.069, P = 0.793 |
| Disease duration (y) | 3.1 ± 2.2 | 3.1 ± 2.0 | 3.2 ± 2.6 | 3.2 ± 2.8 | NA | U = 422.0, p = 0.676 | NA |
| Hoehn and Yahr | 3.2 ± 1.1 | 3.1 ± 1.1 | 3.6 ± 1.1 | 2.1 ± 0.9 | NA | U = 200.5, p<0.001 | NA |
| 3.0T MRI | 14/30 | 10/19 | 4/11 | 12/30 | 16/30 | X² = 0.271, P = 0.602 | X² = 0.267 P = 0.606 |

MSA, multiple system atrophy; PD, Parkinson’s disease; HCs, healthy controls.

TABLE 2 | DWI scores of putaminal hypointensity and other image parameters.

|                | MSA (n = 30) | MSA-P (n = 19) | MSA-C (n = 11) | PD (n = 30) | HCs (n = 30) | MSA vs. PD | MSA vs. HCs |
|----------------|--------------|---------------|----------------|-------------|-------------|------------|-------------|
| DWI scores of putaminal hyperintensity (Left; Right) | | | | | | | |
| 0 score       | 11; 11 | 6; 6 | 5; 5 | 16; 16 | 16; 16 | - | - |
| 1 score       | 5; 4   | 2; 3 | 3; 1 | 9; 9 | 10; 11 | U = 315.5, P = 0.034 | U = 304.0, P = 0.022 |
| 2 score       | 13; 15 | 10; 10 | 3; 5 | 5; 3 | 3; 3 | U = 308.0, P = 0.024 | U = 307.0, P = 0.024 |
| 3 score       | 1; 0   | 1; 0 | 0; 0 | 0; 0 | 1; 0 | - | - |
| Mean score    | 1.1 ± 0.9 | 1.3 ± 0.9 | 0.9 ± 0.9 | 0.6 ± 0.8 | 0.6 ± 0.7 | U = 8.864, P = 0.003 | X² = 10.800, P = 0.001 |
| Unilateral higher score | 1.2 ± 1.0 | 1.3 ± 1.0 | 1.0 ± 1.0 | 0.6 ± 0.8 | 0.6 ± 0.8 | U = 8.864, P = 0.003 | X² = 10.800, P = 0.001 |
| ≥2 score      | 16     | 11    | 5    | 5    | 4    | X² = 8.864, P = 0.003 | X² = 10.800, P = 0.001 |
| Shape of the hypointensity with a score ≥2 | | | | | | | |
| Straight      | 16 | 11 | 5 | 0 | 0 | - | - |
| Arc           | 0 | 0 | 0 | 5 | 4 | - | - |
| Black straight-line sign | 16/30 | 11/19 | 5/11 | 0/30 | 0/30 | 53.3% | 100% |
| Other image parameters | | | | | | |
| SWI scores of putaminal hypointensity ≥2 | 4/6 | 3/5 | 1/1 | 5/21 | 0/19 | 66.7% | 87.5% |
| “hot cross bun” sign | 7/30 | 2/19 | 5/11 | 0/30 | 0/30 | 23.3% | 100% |
| Hyperintense putaminal rim on T2 | 8/30 | 6/19 | 2/11 | 2/30 | 1/30 | 26.7% | 95.0% |
| Brain stem atrophy | 7/30 | 2/19 | 5/11 | 0/30 | 0/30 | 23.3% | 100% |
| Cerebellar atrophy | 15/30 | 7/19 | 8/11 | 1/30 | 0/30 | 50.0% | 98.3% |

MSA, multiple system atrophy; PD, Parkinson’s disease; HCs, healthy controls.

We further graded the “black straight-line sign” into 3 different degrees. As shown in Figure 2, three different layers of the basal ganglia are presented on the axial image. A mild “black straight-line sign” is featured as a light abnormality appearing only in the middle plane. A moderate “black straight-line sign” is an obvious low signal degree appearing at the bottom and the middle planes, with a gradual trend but without pronounced posterolateral to anteromedial differences. An obvious “black straight-line sign” features a pronounced low-signal degree displayed at all three planes, with an obvious gradient from posterolateral to anteromedial shapes. Nonetheless, we did not find any association between the occurrence or severity of the “black straight-line sign” and disease duration or H-Y stages of MSA. Therefore, the emergence of this “black straight-line sign” should be viewed only as a diagnostic marker and not a grading marker of disease severity.

Previous research on hypointense posterior putaminal signals in SWI has mainly focused on the subgroups of MSA-P, while its characteristics in MSA-C were rarely investigated (12, 13, 18). In our study of the “black straight-line sign”, it appeared in a high proportion in both MSA-P and MSA-C, suggesting that this sign has limited significance in distinguishing the subtypes of MSA. This may reflect the fact that both MSA-P and MSA-C have similar neuropathological presentations despite the distributed scope of GCI being different in both subtypes (19). The “black straight-line sign” had comparable sensitivity and specificity in the diagnosis of MSA, which was comparable to the SWI feature of putaminal hypointensity ≥2 (with a sensitivity of 66.7%, and a specificity 87.5%) and cerebellar atrophy (with a sensitivity of 50.0%, and a specificity 98.3%) but better than the other image parameters, including the hyperintense putaminal rim (with a sensitivity of 26.7%, and a specificity 95.0%) and hyperintensity of the pons (“hot cross bun” sign) (with a sensitivity of 23.3% and a specificity 100%) in T2-weighted images, and brain stem atrophy (with a sensitivity of 23.3%, and a specificity of 100%). However, the fact that a hypointense posterior putaminal signal in SWI had a high false positive (5/21,about 24%) in Parkinson’s disease may limit its application. The combination of the “black
The “black straight-line sign” and posterior putaminal hypointensity in SWI may further improve the accuracy of disease diagnosis.

The reason for the appearance of the “black straight-line sign” in DWI remains unknown. Pathological results indicated that the neuronal cell loss, gliosis, and ferritin and Fe (3+) was predominantly located in the posterolateral part of the putamen (20–22). Because SWI sequences are highly sensitive to the paramagnetic effects of iron deposition in the putamen, we speculate that the causality is similar to that of the hypointense signal in the posterior putamen in SWI. Since the DWI sequence is also imaged based on the T2 sequence, we suspect that the appearance of the “black straight-line sign” also reflects the deposition of ferrous or iron ions. In addition, neuropathological and SWI image examinations showed obvious putamen atrophy in MSA (22, 23), which may account for its characteristic shape in DWI (i.e., clearly enclosed by the surrounding structures). More research is needed to explore the reason for the “black straight-line sign” on DWI.

Both 1.5 and 3.0 Tesla MRI scannings were used in this study. Previous studies demonstrated that as the field strength increased the occurrence of hypointensity at the dorsolateral putaminal margin increased in MSA (24). In this study, we also found that subjects that in 3.0 Tesla group had higher scores of hypointensity in the margin of the putamen on DW images. However, the occurrence of “black straight-line sign” in DWI showed no different between 1.5 and 3.0 Tesla MRI groups. Our study has several limitations: firstly, few patients underwent DWI and SWI imaging simultaneously, which may lead to limited accuracy of sensitivity and specificity of posterior putamen low signal sign in SWI. So more research is needed to compare the diagnostic value of the “black straight-line sign” and posterior putamen low signal sign in SWI. Secondly, our study did not include patients with other types of Parkinsonism, including progressive supranuclear palsy, dementia with Lewy body disease which were also difficult to differentiate from MSA in the early stages of the disease. Thirdly, neurologists did not blind to MRI data when establishing the diagnosis of these patients. Although they did not refer to DWI characteristics in diagnosis, it still could be a potential source of bias. Fourthly, other image parameters including the vertical pons hyperintensity which has been reported to be more sensitive than “hot cross bun” sign and “swallow-tail” sign were not evaluated (16, 20). Finally, the absence of a definite postmortem diagnosis increases the likelihood of misdiagnosis in our patients. Patients in the PD group included in the study had a relatively short disease duration (3.2 ± 2.8 years), and it cannot be said with great certainty that some of these patients will not turn out to have MSA-P several years later. Additional studies that investigate the association between DWI and pathological relations are needed.

In conclusion, we evaluated hypointense posterolateral putaminal signal in head DWI—the “black straight-line sign”. This sign had a favorable applicative value comparable to the hypointense putaminal posterolateral signal in SWI. The “black straight-line sign” may be added as a potential imaging marker for the diagnosis of MSA. It will be valuable for differentially diagnosing MSA, PD, and normal subjects in clinical practice.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board and Ethics Committee at Peking University First Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

YZhe and YS contributed to the concept and drafting and revision of the manuscript. XW, YJ, JC, WS, and HZ contributed to the collection of images and clinical data. ZW and YZhu contributed to revision of the manuscript. All authors have read and approved the final manuscript.

FUNDING

The study was supported by Scientific Research Seed Fund of Peking University First Hospital (2018SF033). Funding bodies did not play a role in the collection, analysis, and interpretation of data. Funding bodies did not contribute to the writing of this manuscript.

ACKNOWLEDGMENTS

The authors would thank all the patients and their families for their support of this research.

REFERENCES

1. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. (2015) 372:249–63. doi: 10.1056/NEJMr1311488
2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. (2008) 71:670–6. doi: 10.1212/01.wnl.0000324625.00404.15
3. Li M, Ma Q, Zhao X, Wang C, Wu H, Li J, et al. Dilemma of multiple system atrophy and spinocerebellar ataxias. J Neurol. (2018) 265:2764–72. doi: 10.1007/s00415-018-8876-x
4. Watanabe H, Riku Y, Hara K, Kawabata K, Nakamura T, Ito M, et al. Clinical and Imaging Features of Multiple System Atrophy: Challenges for an Early and Clinically Definitive Diagnosis. J Mov Disord. (2018) 11:107–20. doi: 10.14802/jmd.18020
5. Silva RNDe, Vallortigara J, Greenfield J, Hunt B, Giunti PM. Haddjivassiliou Diagnosis and management of progressive ataxia in adults. *Pract Neurol.* (2019) 19:196–207. doi: 10.1136/practneurrol-2018-002096

6. Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. *Neurobiol Dis.* (2015) 80:29–41. doi: 10.1016/j.nbd.2015.05.004

7. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson’s disease. *Lancet Neurol.* (2019) 18:573–86. doi: 10.1016/S1474-4422(19)30024-9

8. Lee WH, Lee CC, Shyu WC, Chong PN, Lin SZ. Hyperintense putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson’s disease: a susceptibility-weighted imaging study. *Neuroradiology.* (2015) 57:655–69. doi: 10.1007/s00234-015-1515-7

9. Way C, Pettersson D, Hiller A. The ‘Hot Cross Bun’ sign is not always multiple system atrophy: etiologies of 11 cases. *J Mov Disord.* (2019) 12:27–30. doi: 10.14802/jmd.18031

10. Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al. Differentiation of idiopathic Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. *Neuroimage.* (2004) 21:229–35. doi: 10.1016/j.neuroimage.2003.08.028

11. Meijer FJ, van Rumund A, Tulaðhar AM, Aerts MB, Titulaer I, Esselink RA, et al. Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. *Neuroradiology.* (2015) 57:655–69. doi: 10.1007/s00234-015-1515-7

12. Wang N, Yang H, Li C, Fan GX. Luo Using ‘swallow-tail’ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson’s disease: a susceptibility-weighted imaging study. *Eur Radiol.* (2017) 27:3174–80. doi: 10.1007/s00330-017-4743-x

13. Lee JH, Baik SK. Putaminal hypointensity in the parkinsonian variant of multiple system atrophy: simple visual assessment using susceptibility-weighted imaging. *J Mov Disord.* (2011) 4:460–3. doi: 10.14802/jmd.11012

14. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. *Mov Disord.* (2015) 30:1591–601. doi: 10.1002/mds.26424

15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology.* (1967) 17:427–42. doi: 10.1212/WNL.17.5.427

16. Sugiyama A, Yokota H, Yamanaka Y, Mukai H, Yamamoto T, Hirano S, et al. Vertical pons hyperintensity and hot cross bun sign in cerebellar-type multiple system atrophy and spinocerebellar ataxia type 3. *BMC Neurol.* (2020) 20:157. doi: 10.1186/s12883-020-01738-9

17. Carre G, Dietemann JL, Gebus O, Montaut S, Lagha-Boukhiba O, Wirth T, et al. Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria. *J Neurol.* (2020) 267:1269–77. doi: 10.1007/s00415-020-09702-w

18. Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson’s disease and atypical parkinsonism. *Neuroradiology.* (2010) 52:1087–94. doi: 10.1007/s00234-010-0677-6

19. Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. *Mov Disord.* (2014) 29:1720–41. doi: 10.1002/mds.26052

20. Fearney JM, Lees AJ. Striatonigral degeneration. *A clinicopathological study Brain.* (1990) 113:1823–42. doi: 10.1093/brain/113.6.1823

21. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehraein P, et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. *J Neurol Neurosurg Psychiatry.* (1996) 60:98–101. doi: 10.1136/jnnp.60.1.98

22. Matsuue E, Fujii S, Kanasaki Y, Sugihara S, Miyata H, Ohama E, et al. Putaminal lesion in multiple system atrophy: postmortem MR-pathological correlations. *Neuroradiology.* (2008) 50:559–67. doi: 10.1007/s00234-008-0381-y

23. Ren Q, Meng X, Zhang B, Zhang J, Shuai X, Nan X, et al. Morphology and signal changes of the lentiform nucleus based on susceptibility weighted imaging in parkinsonism-predominant multiple system atrophy. *Parkinsonism Relat Disord.* (2020) 81:194–9. doi: 10.1016/j.parkreldis.2020.11.003

24. Watanabe H, Ito M, Fukusaki H, Sendai J, Atsuta N, Kaga T, et al. Putaminal magnetic resonance imaging features at various magnetic field strengths in multiple system atrophy. *Mov Disord.* (2010) 25:1916–23. doi: 10.1002/mds.s.23196

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Wang, Zhao, Jiang, Zhu, Chen, Sun, Wang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.